With patent expirations looming, and Big Pharma pipelines unable to fill the gap, competition for late-stage licensing opportunities continues to drive late stage-deal valuations ever higher. But is this activity effectively pricing some licensors out of range, sending them instead to earlier-stage deals, and driving up prices there accordingly? In the chart below, we've broken out average values of preclinical deals versus late-stage deals (Phase II and III) over the past five years. As late stage values have shot up to the $90+ million range on average since 2000, the average preclinical values since then have risen steadily, from $23 million to $44 million, while deal activity has remained relatively constant (78 preclinical deals in 2000, 82 in 2001, and 74 so far in 2002).
Are Late-Stage Deals Driving Up the Cost of Preclinical Deals?
With patent expirations looming, and Big Pharma pipelines unable to fill the gap, competition for late-stage licensing opportunities continues to drive late stage-deal valuations ever higher. But is this activity effectively pricing some licensors out of range, sending them instead to earlier-stage deals, and driving up prices there accordingly?
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.
Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.